Augmedix, Inc. (OTCMKTS:AUGX - Get Free Report) shares rose 0.4% during mid-day trading on Friday . The stock traded as high as $2.34 and last traded at $2.34. Approximately 167,430 shares were traded during trading, a decline of 75% from the average daily volume of 657,957 shares. The stock had previously closed at $2.33.
Augmedix Stock Up 0.4 %
The company has a current ratio of 1.70, a quick ratio of 1.70 and a debt-to-equity ratio of 3.74. The stock has a 50 day simple moving average of $2.15 and a 200 day simple moving average of $2.25. The firm has a market capitalization of $114.59 million, a PE ratio of -5.44 and a beta of -0.22.
Augmedix (OTCMKTS:AUGX - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $13.66 million during the quarter, compared to analysts' expectations of $13.68 million. Augmedix had a negative return on equity of 980.09% and a negative net margin of 57.70%. As a group, sell-side analysts forecast that Augmedix, Inc. will post -0.48 earnings per share for the current year.
Augmedix Company Profile
(
Get Free Report)
Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Augmedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Augmedix wasn't on the list.
While Augmedix currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
